Stockscreener 앱 받기
37.89
6.55%
2.33
시간 외 거래:
38.70
0.81
+2.14%
전일 마감가:
$35.56
열려 있는:
$35.69
하루 거래량:
6.98M
Relative Volume:
1.95
시가총액:
$4.26B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-40.74
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
+15.94%
1개월 성능:
+25.51%
6개월 성능:
+16.37%
1년 성능:
-32.06%
1일 변동 폭
$35.56
$38.29
1주일 범위
$31.30
$38.29
52주 변동 폭
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
37.89 | 3.58B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics Inc. Builds Base for Possible ReboundCommunity Entry Consensus Trade Ideas Shared - beatles.ru
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts - AOL.com
Viking Therapeutics Surges 6.55% on High-Volume Momentum Ranking 373rd as Liquidity-Driven Strategy Yields 166.71% Return - AInvest
Viking Therapeutics Stock Climbs on Promising Drug Results - TipRanks
Viking Therapeutics' VK2735 maintains competitive edge despite disappointing Eli Lilly data. - AInvest
Viking Therapeutics' VK2735 Shows Promising Phase 1 Results, Justifying Buy Rating - AInvest
Viking Therapeutics Surges 11.54% to 408th in Volume Amid Eli Lilly's Setback - AInvest
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Why Viking Therapeutics Stock is Climbing - TipRanks
Promising Phase 1 Results for Viking Therapeutics’ VK2735 Justify Buy Rating - TipRanks
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - Benzinga
Eli Lilly’s obesity drug data lifts Viking Therapeutics stock By Investing.com - Investing.com Canada
Three Stocks Showing Strong Buy Signals - AInvest
Is It Time to Buy Biotech Stocks? - The Motley Fool
Unlocking Viking Therapeutics' Potential with Upcoming Clinical Data - AInvest
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial - MSN
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True? - MSN
This Biotech Stock Could Soar on Upcoming Clinical Data - AOL.com
Two Biotech Stocks with High Upside Potential: Viking Therapeutics and Recursion Pharmaceuticals - AInvest
What is the risk reward ratio of investing in Viking Therapeutics Inc. stockUnmatched market gains - Jammu Links News
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - The Globe and Mail
What institutional investors are buying Viking Therapeutics Inc. stockNavigate the market with precision tools - Jammu Links News
2 Beaten-Down Stocks With Incredible Upside Potential - Yahoo Finance
When is Viking Therapeutics Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - Jammu Links News
What is the dividend policy of Viking Therapeutics Inc. stockExplosive earnings growth - Jammu Links News
What makes Viking Therapeutics Inc. stock price move sharplyGet professional advice for portfolio optimization - Jammu Links News
Is it the right time to buy Viking Therapeutics Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
Is Viking Therapeutics Inc. stock overvalued or undervaluedFree Stock Selection - Jammu Links News
What are analysts’ price targets for Viking Therapeutics Inc. in the next 12 monthsMarket-beating returns - Jammu Links News
Is Viking Therapeutics the Next Big Biotech Bet? - AOL.com
Viking Therapeutics: A Promising Buy with Strategic Opportunities in Obesity Treatment and Direct-to-Consumer Market - TipRanks
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - AOL.com
Viking Bets Big On Obesity And NASH With Dual-Agonist Pipeline - Finimize
Axsome Therapeutics and Viking Therapeutics: Biotech Stocks to WatchNews and Statistics - IndexBox
Wall Street Predicts Axsome Therapeutics and Viking Therapeutics Stocks to Soar 74% to 159% - AInvest
Why Viking Therapeutics Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
Sentiment Turns Positive on Viking Therapeutics Inc. — Reversal AheadMarket Entry and Exit Point Tips From Traders - metal.it
How does Viking Therapeutics Inc. compare to its industry peersDynamic investment growth - Jammu Links News
Raymond James Financial Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - MarketBeat
Why is Viking Therapeutics Inc. stock attracting strong analyst attentionTriple returns potential - Jammu Links News
What catalysts could drive Viking Therapeutics Inc. stock higher in 2025Rapid market gains - Jammu Links News
What are the technical indicators suggesting about Viking Therapeutics Inc.Unlock steady growth with low-risk stocks - jammulinksnews.com
Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):